Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

J.S. Frenel, J.W. Kim, N. Aryal, R. Asher, D. Berton, L. Vidal, P. Pautier, J.A. Ledermann, R.T. Penson, A.M. Oza, J. Korach, T. Huzarski, S. Pignata, N. Colombo, T.W. Park-Simon, K. Tamura, G.S. Sonke, A.E. Freimund, C.K. Lee, E. Pujade-Lauraine

Open source

DOI: 10.1016/j.annonc.2022.06.011
Published: 2022-10
Container: Annals of Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2022.06.011,
  title = {Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial},
  author = {J.S. Frenel and J.W. Kim and N. Aryal and R. Asher and D. Berton and L. Vidal and P. Pautier and J.A. Ledermann and R.T. Penson and A.M. Oza and J. Korach and T. Huzarski and S. Pignata and N. Colombo and T.W. Park-Simon and K. Tamura and G.S. Sonke and A.E. Freimund and C.K. Lee and E. Pujade-Lauraine},
  year = {2022},
  journal = {Annals of Oncology},
  doi = {10.1016/j.annonc.2022.06.011},
  url = {https://doi.org/10.1016/j.annonc.2022.06.011}
}

RIS

TY  - JOUR
TI  - Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
AU  - J.S. Frenel
AU  - J.W. Kim
AU  - N. Aryal
AU  - R. Asher
AU  - D. Berton
AU  - L. Vidal
AU  - P. Pautier
AU  - J.A. Ledermann
AU  - R.T. Penson
AU  - A.M. Oza
AU  - J. Korach
AU  - T. Huzarski
AU  - S. Pignata
AU  - N. Colombo
AU  - T.W. Park-Simon
AU  - K. Tamura
AU  - G.S. Sonke
AU  - A.E. Freimund
AU  - C.K. Lee
AU  - E. Pujade-Lauraine
PY  - 2022
JO  - Annals of Oncology
DO  - 10.1016/j.annonc.2022.06.011
UR  - https://doi.org/10.1016/j.annonc.2022.06.011
ER  -

APA

Frenel, J., Kim, J., Aryal, N., Asher, R., Berton, D., Vidal, L., Pautier, P., Ledermann, J., Penson, R., Oza, A., Korach, J., Huzarski, T., Pignata, S., Colombo, N., Park-Simon, T., Tamura, K., Sonke, G., Freimund, A., Lee, C., & Pujade-Lauraine, E. (2022). Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Annals of Oncology. https://doi.org/10.1016/j.annonc.2022.06.011

Source records

crossref · retrieved 2026-09-26T05:23:02.863Z